Patents by Inventor Jason Cross

Jason Cross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SYSTEM AND METHOD FOR DISPENSER MANAGEMENT
    Publication number: 20240118717
    Abstract: One or more computing devices, systems, and/or methods are provided. For example, a controller of a dispenser may determine usage data of the dispenser. In association with a replenishment event in which a second refill component mounted to the dispenser is replaced by a first refill component, the controller may (i) determine a next replenishment time of the dispenser based upon the usage data, and/or (ii) transmit an indication of the next replenishment time to a first tag of the first refill component.
    Type: Application
    Filed: October 10, 2023
    Publication date: April 11, 2024
    Inventors: Carey JAROS, Tamara CROSS, Michael BALUCH, Mark BULLOCK, Jason SLATER, Jackson WEGELIN
  • PTPN11 inhibitors
    Patent number: 11945815
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: April 2, 2024
    Inventors: Philip Jones, Barbara Czako, Christopher L Carroll, Pijus Mandal, Jason Cross
  • Substituted heterocyclic inhibitors of PTPN11
    Patent number: 11932643
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: March 19, 2024
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Jason Cross, Jason Burke, Timothy McAfoos, Zhijun Kang
  • Heterocyclic inhibitors of PTPN11
    Patent number: 11840536
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: December 12, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philip Jones, Barbara Czako, Jason Cross, Paul Leonard, Faika Mseeh, Connor Parker
  • Inhibitors of receptor interacting protein kinase I for the treatment of disease
    Patent number: 11753381
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: September 12, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Michael Hamilton, William J. Ray, Fernando Alvarez, Dana E. Pfaffinger, Naphtali Reyna, Jason Cross, Suyambu Kesava Vijayan Ramaswamy
  • Inhibitors of receptor interacting protein kinase I for the treatment of disease
    Patent number: 11718612
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: August 8, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, William J. Ray, Fernando Alvarez, Naphtali Reyna, Jason Cross, Suyambu Kesava Vijayan Ramaswamy
  • Inhibitors of receptor interacting protein kinase I for the treatment of disease
    Patent number: 11690850
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: July 4, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, William J. Ray, Fernando Alvarez, Naphtali Reyna, Jason Cross, Suyambu Kesava Vijayan Ramaswamy
  • HETEROCYCLIC INHIBITORS OF PTPN11
    Publication number: 20230109858
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: July 29, 2022
    Publication date: April 13, 2023
    Inventors: Philip JONES, Barbara CZAKO, Jason CROSS, Paul LEONARD, Faika MSEEH, Connor PARKER
  • Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
    Patent number: 11560366
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 24, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael J. Soth, Kang Le, Philip Jones, Jason Cross
  • Heterocyclic inhibitors of PTPN11
    Patent number: 11466017
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: October 11, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Philip Jones, Barbara Czako, Jason Cross, Paul Leonard, Faika Mseeh, Connor Parker
  • BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE
    Publication number: 20220267311
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Application
    Filed: March 10, 2022
    Publication date: August 25, 2022
    Inventors: Michael J. SOTH, Gang LIU, Kang LE, Jason CROSS, Philip JONES
  • HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
    Publication number: 20220194940
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 23, 2022
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX, Monique NILSSON, Philip JONES, Jason CROSS, Jay THEROFF
  • Heterocyclic inhibitors of tyrosine kinase
    Patent number: 11365189
    Abstract: The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: June 21, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: John Heymach, Jacqulyne Robichaux, Monique Nilsson, Philip Jones, Jason Cross, Jay Theroff
  • PTPN11 INHIBITORS
    Publication number: 20220041594
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 10, 2022
    Inventors: Philip JONES, Barbara CZAKO, Christopher L. CARROLL, Pijus MANDAL, Jason CROSS
  • Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
    Patent number: 11173145
    Abstract: Compounds of formula (VII), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pertaining to said compounds.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: November 16, 2021
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Hamilton, Philip Jones, Alessia Petrocchi, Naphtali Reyna, Jason Cross, Michelle Han, Michael Soth, Timothy McAfoos, Martin Tremblay
  • SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11
    Publication number: 20210317122
    Abstract: The present invention relates to compounds which may be useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Application
    Filed: February 3, 2021
    Publication date: October 14, 2021
    Inventors: Philip JONES, Jason CROSS, Jason BURKE, Timothy MCAFOOS, Zhijun KANG
  • PTPN11 inhibitors
    Patent number: 11104675
    Abstract: The present invention relates to compounds which are useful as inhibitors of PTPN11 for the treatment or prevention of cancer and other PTP-mediated diseases. Disclosed herein are new compounds and compounds based on pyrazolopyrazines and their application as pharmaceuticals for the treatment of disease.
    Type: Grant
    Filed: August 9, 2019
    Date of Patent: August 31, 2021
    Assignee: NAVIRE PHARMA, INC.
    Inventors: Philip Jones, Barbara Czako, Christopher L. Carroll, Pijus Mandal, Jason Cross
  • INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
    Publication number: 20210154204
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: May 27, 2021
    Inventors: Richard T. LEWIS, Matthew HAMILTON, William J. RAY, Fernando ALVAREZ, Naphtali REYNA, Jason CROSS, Suyambu Kesava Vijayan RAMASWAMY
  • BICYCLO[1.1.1]PENTANE INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE
    Publication number: 20210115010
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Application
    Filed: October 20, 2020
    Publication date: April 22, 2021
    Inventors: Michael J. SOTH, Kang LE, Philip JONES, Jason CROSS
  • INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
    Publication number: 20210094921
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Application
    Filed: September 25, 2020
    Publication date: April 1, 2021
    Inventors: Richard T. LEWIS, Matthew Michael HAMILTON, William J. RAY, Fernando ALVAREZ, Dana E. PFAFFINGER, Naphtali REYNA, Jason CROSS, Suyambu Kesava Vijayan RAMASWAMY, Nicole A. RICHARDS